QP6126, an orally bioavailable QPCTL inhibitor, with anti-tumor activity in melanoma tumor model
International Immunopharmacology · 2026-11 · 189 · 117345
DOI: 10.1016/j.intimp.2026.117345 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-11. Verfasst von Longyan Xie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200092, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Aminoacyltransferases, Melanoma, Experimental, Enzyme Inhibitors. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Glutaminyl-peptide cyclotransferase-like protein (QPCTL) is a pivotal post-translational modification enzyme remodeling tumor microenvironment through catalyzing the pyroglutamation (pGlu) at the N-terminus of CD47, CCL2 and CCL7. Inhibiting QPCTL attenuates the CD47-SIRPα interaction and impairs the recruitment of pro-tumoral macrophages, thereby promoting anti-tumor immunity, and has emerged as a potential target for cancer immunotherapy. Nevertheless, the development of QPCTL inhibitors for cancer immunotherapy is still in its early stages. Herein, we report the discovery and characterization of QP6126, a highly potent and orally bioavailable small-molecule QPCTL inhibitor (IC50 of 2.3 nM). Mechanistically, QP6126 effectively ablates the pGlu-CD47 modification, thereby abolishing CD47-SIRPα interaction, and sensitizing melanoma cells to macrophage-mediated phagocytosis. Notably, QP6126 displays significant in vivo antitumor efficacy in B16F10 melanoma mouse model following oral administration. This study establishes QP6126 as a promising candidate for clinical translation and validate QPCTL as a strategic target for diversifying cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200092, China.
- Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Science, Beijing 100049, China. Electronic address: slxu@sim…
- Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200092, China. Electronic address: yulei31@tongji.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xie, L., Zheng, Z., Zhang, X., Sun, Y., Liu, S., Xu, S., & Yu, L. (2026). QP6126, an orally bioavailable QPCTL inhibitor, with anti-tumor activity in melanoma tumor model. International Immunopharmacology, 189, 117345. https://doi.org/10.1016/j.intimp.2026.117345
Vancouver
Xie L, Zheng Z, Zhang X, Sun Y, Liu S, Xu S, et al. QP6126, an orally bioavailable QPCTL inhibitor, with anti-tumor activity in melanoma tumor model. International Immunopharmacology. 2026;189:117345. doi:10.1016/j.intimp.2026.117345
BibTeX
@article{Xie2026,
author = {Xie, Longyan and Zheng, Zening and Zhang, Xindan and Sun, Yaoliang and Liu, Siqi and Xu, Shilin and Yu, Lei},
title = {QP6126, an orally bioavailable QPCTL inhibitor, with anti-tumor activity in melanoma tumor model},
journal = {International Immunopharmacology},
year = {2026},
volume = {189},
pages = {117345},
doi = {10.1016/j.intimp.2026.117345}
}
EUVIMED